Synchronous resection of primary and liver metastases for neuroendocrine tumors

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4270-4277

  Gaujoux, Sébastien ^a   Gonen, Mithat ^a   Tang, Laura ^a   Klimstra, David ^a   Brennan, Murray F ^a   D'Angelica, Michael ^a   DeMatteo, Ronald ^a   Allen, Peter J ^a   Jarnagin, William ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; OCTREOTIDE;

ABLATION THERAPY; ADULT; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TUMOR; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIMARY TUMOR; REVIEW; SURGICAL APPROACH; SYNCHRONOUS LIVER RESECTION; TREATMENT OUTCOME; TRISECTIONECTOMY; TUMOR VOLUME;

FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84876469818     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2462-8     Document Type: Review

References (44)

1. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083-92. (Pubitemid 41815799)
2. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490-500.
3. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813-29. (Pubitemid 27076348)
4. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009;(1):CD007060.
5. Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. 2008;113:126-34. (Pubitemid 351976393)
6. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37. (Pubitemid 36759176)
7. McKenzie S, Lee W, Artinyan A, et al. Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas. J Gastrointest Surg. 2010;14:1796-803.
8. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375-82. (Pubitemid 36515325)
9. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-81.
10. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12:231-42. (Pubitemid 36210867)
11. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845-51. (Pubitemid 44808610)
12. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273-81. (Pubitemid 46148487)
13. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36-42.
14. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741-51.
15. Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9:855-62. (Pubitemid 35265635)
16. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45. (Pubitemid 30181109)
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13. (Pubitemid 38963009)
18. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655-64.
19. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepa-tectomy for hepatobiliary malignancy justified? Ann Surg. 2004;239:722-30.
20. D'Angelica M, Martin RC 2nd, Jarnagin WR, et al. Major hepa-tectomy with simultaneous pancreatectomy for advanced hepa-tobiliary cancer. J Am Coll Surg. 2004;198:570-6. (Pubitemid 38446531)
21. Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003;197:233-41.
22. De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduo-denectomy: a dual-center analysis. Ann Surg. 2010;252:142-8.
23. Ardengh JC, de Paulo GA, Ferrari AP. EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. Gastrointest Endosc. 2004;60:378-84.
24. Figueiredo FA, Giovannini M, Monges G, et al. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009;70:907-14.
25. Bettini R, Mantovani W, Boninsegna L, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis. 2009;41:49-55.
26. Wagnetz U, Jaskolka J, Yang P, Jhaveri KS. Acute ischemic cholecystitis after transarterial chemoembolization of hepatocel-lular carcinoma: incidence and clinical outcome. J Comput Assist Tomogr. 2010;34:348-53.
27. Chua HK, Sondenaa K, Tsiotos GG, et al. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum. 2004;47: 1310-6. (Pubitemid 39180206)
28. Norlen O, Hessman O, Stalberg P, et al. Prophylactic cholecys-tectomy in midgut carcinoid patients. World J Surg. 2010;34: 1361-7.
29. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141: 1000-4. (Pubitemid 44583257)
30. Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138:859-66. (Pubitemid 36960947)
31. Chen SY, Liu TY, Chen MJ, et al. Seroprevalences of hepatitis B and C viruses and Helicobacter pylori infection in a small, isolated population at high risk of gastric and liver cancer. Int J Cancer. 1997;71:776-9.
32. Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a ''thin slice'' pathological examination: they are many more than you think. Ann Surg. 2010;251: 307-10.
33. Hammel P. Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer? Nat Clin Pract Oncol. 2007;4:460-1. (Pubitemid 47393801)
34. Kianmanesh R, Sauvanet A, Hentic O, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247: 659-65. (Pubitemid 351440617)
35. Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol. 2009;100:635-8.
36. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144:645-53.
37. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92.
38. Chamberlain RS, Sakpal SV. A comprehensive review of single-incision laparoscopic surgery (SILS) and natural orifice transluminal endoscopic surgery (NOTES) techniques for cholecystectomy. J Gastrointest Surg. 2009;13:1733-40.
39. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372-7.
40. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-12.
41. Chatzipantelis P, Konstantinou P, Kaklamanos M, et al. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer. 2009;117:211-6.
42. Lin O, Olgac S, Green I, et al. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol. 2003; 120:209-16. (Pubitemid 37046355)
43. Garin E, Le Jeune F, Devillers A, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858-64.
44. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press, 2010.